Skip to content
Trial Eligibility
Menu

A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT07843459

This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .

Summary

The purpose of this study is to see how safe LY4560736 is and to see how much and how quickly LY4560736 gets into the bloodstream. For healthy participants, the study also looks at how much LY4560736 gets into the brain. This part of the study lasts up to 13 weeks which includes staying in the Clinical Research Unit (CRU) for at least 4 days. This group will include Japanese participants, and the Sponsor may choose to enroll Chinese participants.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Healthy Volunteers
  • Alzheimer Disease
  • Amyloid
  • Plaque, Amyloid
  • Plasma

Eligibility basics and study details

Study type
Interventional
Phase
Phase 1
Ages
18 to 85 years
Sex
All
Healthy volunteers
Accepted
Sponsor
Eli Lilly and Company
Last updated on ClinicalTrials.gov
November 18, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

California · 2

  • CenExel ACT · Anaheim, CA
  • Collaborative Neuroscience Network - CNS · Los Alamitos, CA

Florida · 1

  • Fortrea Clinical Research Unit · Daytona Beach, FL

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.